Sunday, 27 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14486
Articles
Company
Drug
Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review
February 19, 2025
Company
Drug
Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC
February 19, 2025
Company
GSK and Abbott Announce Leadership Changes in Key Roles
February 19, 2025
Company
Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation
February 19, 2025
Company
Deals
QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium
February 19, 2025
Company
Deepwise Information Integrates DeepSeek into Medical Data Platform
February 19, 2025
Company
Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round
February 19, 2025
Company
Drug
InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL
February 18, 2025
Company
Drug
Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA
February 18, 2025
Company
Drug
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
February 18, 2025
Company
Deals
Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion
February 18, 2025
Company
Drug
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
February 18, 2025
1
2
…
449
450
451
452
453
…
1,207
1,208
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?